Amprologix, launched in 2018 in collaboration with University of Plymouth, has pioneered a drug discovery programme focused on identifying the next generation of antibiotics.
Partnered with world-leading biotechnology company Ingenza LTD for manufacturing, Amprologix is in a position of strength to combat the growing problem of antibiotic resistance.
One of the key advantages of Amprologix' work is the use of Artificial Intelligence to accelerate research.
By partnering with STFC (Science & Technology Facilities Council), Amprologix is able to utilize cutting-edge machine learning algorithms to improve antibiotic properties.
The team
Gordon Barker
CEO
Gordon is a serial entrepreneur who has helped negotiate co-development / licensing deals with numerous pharmaceutical majors and helped found and manage a number of University biotech spinouts, including: Microbiosensor, Conformetrix, Ai2 and Gentronix.
Mathew Upton
CSO
Matt is a professor of Medical Microbiology at the University of Plymouth and co-founder of Amprologix. Matt discovered the NI01 peptide family whilst working at Manchester University. Matt is also a founder and director of University of Manchester spinout company Spectromics.
Ian Fotheringham
CHAIRMAN
Ian is the MD and co-founder of industrial biotechnology company Ingenza Ltd. Ian and Ingenza bring unique expertise in synthetic biology and production strain optimization to Amprologix.
